Evomela is a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating multiple myeloma. Evomela is often combined with other drugs such as Velcade or Thalomid and a corticosteroid. Evomela is also known by its drug name, melphalan.
Evomela is an anticancer drug used in chemotherapy. Evomela is a member of a class of drugs called alkylating agents. Evomela is believed to work by preventing the production of DNA in cells, thereby blocking cancer cell division.
How do I take it?
Evomela is administered as an intravenous infusion during chemotherapy treatment.
The FDA-approved label for Evomela lists common side effects including decreased blood cell count, fatigue, mouth sores, nausea, vomiting, diarrhea, increased risk for infection, and anemia.
Rare but serious side effects listed for Evomela include stomach toxicity, fetal harm in pregnant women, and the risk of permanent infertility in both men and women.
For more details about this treatment, visit:
Evomela — Spectrum
Drug Therapy for Multiple Myeloma — American Cancer Society